Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "Mitochondria-Targeted Drug Development 2022 Boston US"

From Bioblast
Line 36: Line 36:
== Health and Safety == Β 
== Health and Safety == Β 
:::: All attendees will be required to complete a health declaration prior to attending the event. As part of this, attendees must declare that they are either fully vaccinated and /or have completed a negative Lateral Flow Test or PCR Test within 48 hours of the event*.
:::: All attendees will be required to complete a health declaration prior to attending the event. As part of this, attendees must declare that they are either fully vaccinated and /or have completed a negative Lateral Flow Test or PCR Test within 48 hours of the event*.
For further information around Health and Safety onsite, please visit the FAQ page [https://customerportal.hansonwade.com/attendee-registration/health-safety-measures/ here].
:::: For further information around Health and Safety onsite, please visit the FAQ page [https://customerportal.hansonwade.com/attendee-registration/health-safety-measures/ here].
:::: *Please note, this is subject to change at any time without prior notice.
:::: *Please note, this is subject to change at any time without prior notice.



Revision as of 11:52, 22 November 2021


MitoGlobal         MitoGlobal Societies         MiPsociety         Asia Society for Mitochondrial Research and Medicine         MitoGlobal Events         MitoGlobal first



Mitochondria-Targeted Drug Development 2022 Boston US

Publications in the MiPMap
Mitochondria Targeted Therapeutics
Boston, MA US, 2022 Feb 22-24. 2nd Annual Mitochondria-Targeted Drug Development - Overcome the Challenge of Treating Unmet Medical Needs Caused by Mitochondrial Dysfunction

Β» https://mitochondria-targets.com/

hansonwade (2022-02-22) MitoGlobal

Abstract: 2nd Annual Mitochondria-Targeted Drug Development, Boston MA, US, 2022.


General information

The Digital Mitochondria-Targeted Drug Development is the only industry-led meeting focused on end-to-end mitochondria-targeting. Incorporating insights from leading academics and pioneering biotech, this forum will specifically focus on targeting mitochondrial dysfunction to develop therapies for chronic diseases caused by mitochondrial DNA mutation/nuclear DNA mutations, muscle dystrophy diseases/muscle loss, metabolic disorders, neurodegenerative disease, and conditions linked to oxidative damage.
Join 80+ leading experts as they navigate common challenges and opportunities for treating unmet medical needs caused by mitochondrial dysfunction. Mitobridge/Astellas, Minovia Therapeutics, Abliva, GenSight Biologics, Stealth Biotherapeutics and many more will unite drive to better understand how to create effective and scalable mitochondrial therapies.
Download the brochure here

Program

The program is available here

Registration

Register here
Early bird & Team Discounts Available until Dezember, 17

Organizer

Hanson Wade
Mail: [email protected]
https://hansonwade.com/

Speaker

See the full list of speakers here

Health and Safety

All attendees will be required to complete a health declaration prior to attending the event. As part of this, attendees must declare that they are either fully vaccinated and /or have completed a negative Lateral Flow Test or PCR Test within 48 hours of the event*.
For further information around Health and Safety onsite, please visit the FAQ page here.
*Please note, this is subject to change at any time without prior notice.


MitoGlobal
Listed under MitoGlobal Events.


Labels:






2022, MitoGlobal